VanEck Environmental Services ETF EVX
41.67 USD +0.84 (+2.05%)
Nov 4, 2026, 3:17 PM EST
41.09 Day range 41.67
36.55 52-week range 42.44
- YTD
- +9.00%
- 1 year
- +12.47%
- Market cap
- 100.46M
- EPS (ttm)
- 1.53
- P/E ratio
- 27.20
- YTD return
- +9.00%
- 1-year return
- +12.47%
- Volume
- 11.45K
- Avg volume
- 7.28K
- Open
- 41.49
- Previous close
- 40.83
- Day's range
- 41.09 – 41.67
- 52-week range
- 36.55 – 42.44
2Y +5.36 (+14.76%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 184.91
- 200-day average
- 173.93
About VanEck Environmental Services ETF
The fund normally invests at least 80% of its total assets in common stocks and ADRs of companies involved in the environmental services industry. The index is designed to measure the performance of widely held, highly capitalized companies engaged in business activities that may benefit from the global increase in demand for consumer waste disposal, removal and storage of industrial by-products, and the management of associated resources. It is non-diversified.
News
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting 
Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting 
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 
These 3 ETFs Could Benefit From the Parts of Inflation That Won't Go Away 
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting 
Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program 
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 
Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
Your note
Sign in to keep a note on EVX — it syncs with the Stock Master app.